Clarametyx Biosciences is a late preclinical stage biotechnology company developing targeted, immune-enabling biologic therapies to counter persistent infections associated with biofilms.
Vaxcyte is a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide. The Company’s cell-free protein synthesis platform, comprising the XpressCFTM platform, exclusively licensed from Sutro Biopharma, Inc., together with Vaxcyte’s proprietary know-how, enables the design and production of protein carriers and antigens, the critical building blocks of vaccines, in ways that the Company believes conventional vaccine technologies currently cannot. In addition to its pneumococcal conjugate vaccines in development, VAX-24 and VAX-XP, Vaxcyte is leveraging its proprietary platform to advance other novel vaccines, including a prophylactic vaccine to prevent Group A Strep infections (VAX-A1) and a therapeutic vaccine to treat periodontal disease (VAX-PG).
Accelerate Diagnostics is a medical device company dedicated to providing solutions to the global challenge of drug-resistant organisms and hospital-acquired infections. It is focused on developing and commercializing innovative instrumentation for the rapid identification and antibiotic susceptibility testing of infectious pathogens. The Company’s revolutionary BACcel platform utilizes a proprietary culture-free process, with both genomic and phenotypic detection technologies, that significantly decreases time to result while achieving high sensitivity and specificity. It was founded in 2004 and is headquartered in Tucson, Arizona.
Bioversys AG is a biopharmaceutical company located in Basel that focuses on research and development of new drugs and compounds, which switch off drug resistance within bacterial pathogens and restore the efficacy of approved antibiotics. Their focus is on creating therapies to combat multidrug-resistant (MDR) bacterial infections, a major global health issue. BioVersys’ proprietary TRIC (Transcriptional Regulator Inhibitory Compounds) technology platform is designed to identify new treatments by inhibiting bacterial resistance mechanisms, thereby making antibiotics more effective.
SNIPR Biome is a operator of a discovery stage biotech company intended to revolutionize the treatment of microbial diseases. The company uses CRISPR technology that can subvert elements of the endogenous bacterial CRISPR machinery to eliminate hazardous bacteria in vivo, providing the health professionals with medicines that selectively target and kill bacteria with specific DNA sequences.
Basilea Pharmaceutica Ltd. is headquartered in Basel, Switzerland, and listed on the SIX Swiss Exchange (SIX: BSLN). Through the integrated research, development and commercial operations of its Swiss subsidiary Basilea Pharmaceutica International Ltd., the company focuses on providing innovative pharmaceutical products in the therapeutic areas of bacterial infections, fungal infections and oncology, targeting the medical challenge of rising resistance and nonresponse to current treatment options.
Summit Therapeutics is a clinical-stage drug discovery and development company. The company's new mechanism antibiotics are designed to become the new standards of care for the benefit of patients and create value for payors and healthcare providers.
SpeeDx specializes in molecular diagnostic solutions that go beyond simple detection to offer comprehensive information for improved patient management. Innovative real-time polymerase chain reaction (qPCR) technology has driven market-leading multiplex detection and priming strategies. Product portfolios focus on multiplex diagnostics for sexually transmitted infection (STI), antibiotic resistance markers, and respiratory disease.
GenomeKey is an award-winning, early-phase company that is exploiting innovative genomic technology and cutting-edge AI machine learning to address critical healthcare challenges.
Baebies was founded in 2014 by Richard West and Vamsee Pamula, following the successful development of digital microfluidics technology, the development and launch of multiple products, and the eventual sale of Advanced Liquid Logic to Illumina, Inc. Baebies has now licensed its core technology, acquired product and manufacturing assets, and built seasoned management and technical teams to pursue opportunities in newborn screening and near-patient diagnostic testing. Baebies newborn screening platform, SEEKER, is FDA authorized and CE marked. The FINDER and FINDER 1.5 platforms are CE marked and the FINDER 1.5 SARS-CoV-2 test received emergency use notification from the FDA. Baebies’ digital microfluidics technology is a recipient of multiple awards, including the coveted Disruptive Technology Award from AACC in their ‘search for the next innovative testing solution that will transform patient care Baebies' mission is to save lives and make lives better by bringing new technologies, new tests, and new hope to newborns, patients, and healthcare professionals worldwide.
Phico Therapeutics is a biotechnology company developing a novel platform technology which it believes could form the basis for a new generation of antibiotics to overcome antibacterial resistance.
Novel Microdevices is a medical device startup that develops a handheld point-of-care medical device to facilitate molecular diagnostics. Its device uses microfluidics to analyze a raw biological sample directly at the point of care and takes only 30 minutes to interpret quality results that enable healthcare professionals to achieve lab-quality results in a lab-free environment. The company was founded by Andrea Pais in 2014 and is headquartered in Baltimore, Maryland.
The Jenner Institute was founded in November 2005 to develop innovative vaccines against major global diseases. Uniquely it focuses both on diseases of humans and livestock and tests new vaccine approaches in parallel in different species. A major theme is translational research involving the rapid early-stage development and assessment of new vaccines in clinical trials. The Institute comprises the research activities of over 30 Jenner Investigators who head leading research groups spanning human and veterinary vaccine research and development. Together the Institute Investigators comprise one of the largest non-profit sector research and development activities in vaccinology. Jenner Institute Investigators, through the support of many funders, are developing new vaccine candidates against major global infectious diseases. New vaccines against malaria, tuberculosis and HIV are currently in field trials in the developing world. Research is also underway on livestock vaccines against foot and mouth disease, avian influenza, bovine tuberculosis and other major causes of economic loss.
Affinivax is a biopharmaceutical company developing vaccines used to enhance the depth of protection against infectious diseases. This novel and highly efficient vaccine conjugation technology – named MAPS for Multiple Antigen Presenting System – has the potential to deliver novel vaccines that offer broader disease coverage than existing vaccines, as well as protect against infectious diseases for which there are no effective immunization strategies today. The company is rapidly advancing a lead program targeting Streptococcus pneumoniae (pneumococcus), a pathogen that is responsible for significant morbidity and mortality in children and adults worldwide. Affinivax was established based on the knowledge and insights of world-leading experts in the fields of infectious diseases and vaccines. The company is backed by an investment from the Bill & Melinda Gates Foundation and has an exclusive license from Boston Children’s Hospital for intellectual property related to the MAPS technology platform.
GlaxoSmithKline is a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer. The company aims to bring differentiated, high-quality and needed healthcare products to as many people as possible, with its 3 global businesses, scientific and technical know-how, and talented people. GSK's Pharmaceuticals business has a broad portfolio of innovative and established medicines with commercial leadership in respiratory and HIV. Our R&D approach focuses on science related to the immune system, the use of genetics, and advanced technologies. The Vaccines business has a broad portfolio and innovative pipeline of vaccines to help protect people throughout life. It delivers over two million vaccine doses per day to people living in over 160 countries. The Consumer Healthcare business develops and markets an innovative portfolio of consumer preferred and expert-recommended brands in the Pain relief, Respiratory, Digestive health, Oral Health, Nutrition, and Skin health categories.
The University of Queensland (UQ) has maintained a global reputation for delivering knowledge leadership for a better world. The most prestigious and widely recognized rankings of world universities consistently place UQ among the world's top universities. UQ has also won more national teaching awards than any other Australian university. This commitment to quality teaching empowers our 53,600 current students, who study across UQ’s three campuses, to create positive change for society.
Institute for Molecular Bioscience is a research institute at The University of Queensland.
Rapid digital detection of infections and treatment optimization. Accurate, rapid, digital detection of infections in any bodily fluid to indicate in real-time which drugs will be most effective at the point-of-prescription. Today the US spends $20B+ on infection detection. The market for efficient bacteria resistance detection has enormous potential. Avails Medical is pioneering the current diagnostics market with a groundbreaking technology that targets this global health threat. Avails Medicals' cost-effective platform will transform the diagnostics market by enabling for the first time diagnostic-guided therapy at the point-of-care, reducing time-to-treatment from days to minutes.
Lumen Bio is a clinical-stage biotechnology company developing topically and mucosally delivered biologic drugs to treat and prevent highly prevalent diseases.
Polyphor is a Swiss Pharma company focusing on the discovery and development of macrocycle drugs addressing high unmet medical needs. Polyphor was founded in 1996 and is a clinical stage, privately held Swiss specialty pharma company, based in Allschwil near Basel. It focuses on the development of macrocycle drugs that address antibiotic resistance and severe respiratory diseases.
The Helmholtz Centre for Infection Research applies basic research findings to medical applications. The company's goal is to lay the groundwork for new diagnostic tools, drugs, and therapies for infectious diseases. It researches pathogens that are medically important or can be used as models for infection research. Understanding these mechanisms will aid in the development of new drugs and vaccines to combat infectious diseases.
Vaxcyte is a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide. The Company’s cell-free protein synthesis platform, comprising the XpressCFTM platform, exclusively licensed from Sutro Biopharma, Inc., together with Vaxcyte’s proprietary know-how, enables the design and production of protein carriers and antigens, the critical building blocks of vaccines, in ways that the Company believes conventional vaccine technologies currently cannot. In addition to its pneumococcal conjugate vaccines in development, VAX-24 and VAX-XP, Vaxcyte is leveraging its proprietary platform to advance other novel vaccines, including a prophylactic vaccine to prevent Group A Strep infections (VAX-A1) and a therapeutic vaccine to treat periodontal disease (VAX-PG).
Clarametyx Biosciences is a late preclinical stage biotechnology company developing targeted, immune-enabling biologic therapies to counter persistent infections associated with biofilms.
Locus Biosciences is a developer of a CRISPR-engineered precision antibacterial platform designed to revolutionize the treatment of bacterial disease. The company's platform combines the antibacterial power of CRISPR-Cas3 with the efficient, safe delivery of bacterial viruses called bacteriophage, enabling physicians to begin treatment more quickly, resulting in a better medical outcome.
Cellics is committed to saving lives and improving patients’ health using innovative biomimetic nanomedicines. It was created with the goal of applying Nanosponge Technology to treat and prevent diseases. It aims to employ innovative biomimetic nanomedicines to address serious diseases with a high unmet medical need. The company’s initial primary focus is on autoimmune and inflammatory diseases and difficult to treat infectious diseases. Additionally, Cellics is seeking to develop best-in-class vaccines for various diseases. The company is currently on schedule to advance its lead product candidate CTI-005 to human clinical trials for the treatment of bacterial pneumonia. It is the passion and goal of Cellics to use advanced technology to help human beings live healthier and longer lives. The company was founded in 2014 and is headquartered in San Diego, California.
Polyphor is a Swiss Pharma company focusing on the discovery and development of macrocycle drugs addressing high unmet medical needs. Polyphor was founded in 1996 and is a clinical stage, privately held Swiss specialty pharma company, based in Allschwil near Basel. It focuses on the development of macrocycle drugs that address antibiotic resistance and severe respiratory diseases.
GangaGen, Inc. is a clinical-stage biotechnology company focused on developing novel therapeutic proteins targeting infectious diseases in areas of high unmet need such as MRSA and other drug resistant bacteria. Using a proprietary platform, GangaGen is developing highly-specific therapeutic proteins called ectolysins to target clinically meaningful types of bacteria. The company’s lead ectolysin, P128, is a recombinant protein that binds to and kills Staphylococcus, including methicillin-resistant strains of S. aureus (MRSA).
GlaxoSmithKline is a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer. The company aims to bring differentiated, high-quality and needed healthcare products to as many people as possible, with its 3 global businesses, scientific and technical know-how, and talented people. GSK's Pharmaceuticals business has a broad portfolio of innovative and established medicines with commercial leadership in respiratory and HIV. Our R&D approach focuses on science related to the immune system, the use of genetics, and advanced technologies. The Vaccines business has a broad portfolio and innovative pipeline of vaccines to help protect people throughout life. It delivers over two million vaccine doses per day to people living in over 160 countries. The Consumer Healthcare business develops and markets an innovative portfolio of consumer preferred and expert-recommended brands in the Pain relief, Respiratory, Digestive health, Oral Health, Nutrition, and Skin health categories.
Mutabilis is discovery of new therapeutic targets for the development of anti-infectives. Mutabilis is a biopharmaceutical company specialised in the discovery and development of anti-infectives. Mutabilis discovers and develops innovative anti-infectives, a novel class of drug addressing the current issues arising from resistance to antibiotics and targeting severe bacterial infections. Mutabilis’ new therapies target nosocomial infections in particular.
MicuRx discovers and develops novel antibiotics to combat drug resistant bacterial infections. Founded in 2007, MicuRx employs a hybrid U.S./China business model to capitalize on the global opportunities afforded by U.S. research and development coupled with the high-quality, cost-efficient scientific resources in China. Shanghai MicuRx was established and as of 2021 commercializes our agent, contezolid, in China. Global clinical studies are on-going.
Evotec is a drug discovery alliance and development partnership rapidly progressing innovative product approaches with pharmaceutical and biotechnology companies, academics, patient advocacy groups, and venture capitalists. Drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licencing of innovative drug candidates, and consulting arrangements.
ContraFect is a biotechnology company pioneering the use of monoclonal antibodies to treat life-threatening infectious diseases. It addresses multi-drug resistant infections using therapeutic products from its lysin and monoclonal antibody platforms to target the conserved regions of either bacteria or viruses. Its novel lysins are enzymes that are produced in the life cycle stage of bacteriophage, a virus that infects and kills bacteria. The company was founded in 2008 and is headquartered in Yonkers, New York.
Vaxdyn develops vaccines using novel technology. They offers pathogen vaccines for preventing antibiotics-resistant infections. Their customers' inquiries are addressed through phone, email, and online applications.
Eligobiotics is a developer of antibiotics intended to treat microbiome precision and bacteria-associated diseases. The company's antibiotics combine CRISPR/Cas system with engineered phage capsids, to develop antimicrobials that are used to eradicate resistant pathogens or virulent bacteria within the human microbiome, enabling clients to get next-generation antimicrobials to treat diseases caused by superbugs.
Amicrobe, Inc. is an advanced biomaterials company with innovative product candidates designed to prevent and treat infections. The Company’s new, synthetic block copolypeptides (A-Blocks) are engineered to provide broad antimicrobial activity and superior tissue coverage when our natural barriers of defense are broken in surgery, trauma / burns, and diabetic foot ulcers.
Institute for Molecular Bioscience is a research institute at The University of Queensland.
Microbion is a pharmaceutical company that focuses on the development of therapeutics for the treatment of bacterial infections. It develops bismuth-thiols to prevent microbial biofilms from forming on medical devices implanted in the body and to prevent microbial biofilms in agricultural crops and industrial surfaces, including ships’ hulls, pulp and paper, and oil industries. It was founded in 1982 and headquartered in Bozeman, Montana.
The future of infectious disease diagnostics starts at Day Zero. By using whole-genome sequencing (WGS) and our proprietary enabling technologies, Day Zero is creating a new class of sequencing-based in-vitro diagnostics that generates clinically actionable data at scale. Our technologies include novel sample preparation methods enabling unprecedented ultra-high enrichment of pathogen DNA for sequencing directly from clinical samples, machine learning algorithms that provide clinically actionable diagnostic results, and a world-class database of WGS and drug efficacy profiles. Day Zero Diagnostics is on a mission to transform the way infectious disease diagnostics are performed by generating the stream of real-time sequencing data required to change how we track, manage and combat infectious diseases. With an enormous unmet clinical and economic need, we are targeting bloodstream infections and sepsis for our first application. The life expectancy of a patient with septic shock is 24 hours without fast effective antibiotic treatment. However, even when successful, current diagnostics take 2-5 days to identify the pathogen AND provide its antibiotic susceptibility profile. The lack of rapid, accurate, and comprehensive diagnostics, forces physicians to “carpet bomb” patients with severe infections with powerful, yet toxic, broad-spectrum antibiotics, which is not only ineffective in many cases but can also lead to significant morbidity and mortality. Day Zero delivers a complete diagnosis, including both the species and antibiotic resistance profile, in hours vs. days, enabling the physician to use a targeted treatment on day zero of hospital admission and resulting in better patient outcomes and cost savings.
Module Innovations is a healthcare solutions provider that provides improved disease management for infectious diseases and antimicrobial resistance (AMR). Its portable, affordable, and rapid point-of-care diagnostic platform with built-in wireless connectivity provides the real-time information required to improve clinical outcomes for individual patients and clinicians' informed decision-making. Module's initial products will target pathogens that cause urinary tract infections (UTIs), such as E. coli, Klebsiella, Pseudomonas, and Enterococci for rapid pathogen identification and AST. Module uses its patented SDSAN technology to provide UTI ID in 15 minutes and antibiotic susceptibility information in 2 hours.
Peptilogics is a clinical-stage biotechnology company that designs and develops novel peptide therapeutics. Through their computational platform, Peptilogics is radically altering drug discovery by not only uncovering new, previously unexplored chemical design space, but ensuring that each potential therapeutic is biologically viable and scalable to manufacture. Peptilogics' lead clinical stage peptide therapeutic, PLG0206, is a novel, broad-spectrum anti-infective that has been granted FDA Orphan Drug Designation and Qualified Infectious Disease Product Designation for its initial focus on the treatment of prosthetic joint infections, an unmet medical need.
Lytica Therapeutics, Inc. is a biotechnology company focused on developing novel peptide therapeutics.
Facile Therapeutics is a biotechnology company that develops therapeutic drugs for clostridium difficile infection. The company demonstrated Ebselen, an anti-toxin that doesn't cause the death of healthy gut bacteria that makes the colon resistant to C diff reinfection. Facile Therapeutics was founded in 2017 by Marc Navre and Matthew Bogyo and is based in Belmont, California.
Pattern Bioscience is a privately held in vitro diagnostics company founded in 2016 to help combat the problem of antibiotic resistance. The pattern is developing a next-generation clinical microbiology platform based on its patented phenotypic single-cell technology that can identify pathogens and determine their antibiotic response without the need for traditional time-consuming culture steps. Pattern’s Digital CultureTM technology relies on functional endpoints that encompass all possible resistance mechanisms, resulting in a more comprehensive and reliable diagnosis compared to rapid genotypic tests. The platform will deliver more reliable diagnoses days faster than the current standard of care.
Centauri is developing novel immunotherapeutics with a dual mechanism of action comprising (1) a moiety directly targeting cell surface antigens and (2) a glycan effector domain which triggers a potent pre-existing polyclonal immune response. This immune response triggers cell death through engagement with the target, enhanced complement fixation, antibody dependent cellular cytotoxicity, and phagocytosis by myeloid cells due to polyclonal antibody decoration of the target cell. Centauri has generated excellent pre-clinical in vitro data demonstrating the potent enhancement of complement fixation and opsonophagocytosis of anti-bacterial and oncology therapeutics as well as in vivo PoC data in multiple models of infection.
Antabio is a private biopharmaceutical company developing novel antibacterial resistance-breakers to treat drug-resistant infections in areas of highest unmet medical need. It develops stand-alone inhibitors of bacterial metalloenzymes that can be combined with various antibiotics to restore their activity against the most critical pathogens. The company's novel inhibitor of bacterial Metallo ß-lactamases (“MBLs”) which will be combined with a carbapenem to fill an important gap in the treatment of drug-resistant infections. They develop a novel, safe and efficacious inhibitor of bacterial Metallo ß-lactamases to be combined with a carbapenem for the treatment of drug-resistant nosocomial infections. Antabio received a Wellcome Trust Seeding Drug Discovery Award. The company was founded in 2009 and is headquartered in Labege, France.
The University of Queensland (UQ) has maintained a global reputation for delivering knowledge leadership for a better world. The most prestigious and widely recognized rankings of world universities consistently place UQ among the world's top universities. UQ has also won more national teaching awards than any other Australian university. This commitment to quality teaching empowers our 53,600 current students, who study across UQ’s three campuses, to create positive change for society.
HelixBind is a Massachusetts-based company that operates in the biotechnology sector. The company was founded in 2012 and is based in Worcester, Massachusetts.
Vedanta Biosciences is a developer of immunotherapies designed to treat immune-mediated and infectious diseases. It includes a suite of proprietary assays to select pharmacologically potent strains, vast proprietary datasets from human interventional studies, and facilities for cGMP-compliant manufacturing of rationally defined bacterial consortia in powder form to help physicians have access to live bacteria drugs to treat autoimmune and inflammatory diseases easily.
Venatorx Pharmaceuticals is a private company that focuses on the discovery and development of novel anti-infectives to treat multi-drug-resistant (MDR) bacterial infections and hard-to-treat viral infections. The company was founded in 2010 and is headquartered in Malvern, Pennsylvania.
Techulon is a biotech firm located in Blacksburg, Virginia. Their headquarters and laboratories are located in the Virginia Tech Corporate Research Center, and their products derive from patents that we license from Virginia Tech. Their main laboratory is outfitted with equipment for the development, manufacture and commercialization of biopolymers applicable to research, therapeutics, energy and sustainability.
Bioversys AG is a biopharmaceutical company located in Basel that focuses on research and development of new drugs and compounds, which switch off drug resistance within bacterial pathogens and restore the efficacy of approved antibiotics. Their focus is on creating therapies to combat multidrug-resistant (MDR) bacterial infections, a major global health issue. BioVersys’ proprietary TRIC (Transcriptional Regulator Inhibitory Compounds) technology platform is designed to identify new treatments by inhibiting bacterial resistance mechanisms, thereby making antibiotics more effective.
Trellis Bioscience develops a technology platform for cellular informatics. The company's technology has applications in the discovery and production of therapeutic monoclonal antibodies. Its cell biology platform provides a direct readout at the single cell level for monitoring activity of diverse cell types and quantifying the impact of potential therapeutic interventions. The company is based in San Francisco, California.
Procarta Biosystems Ltd., established in 2007 by the scientific founders, Dr. Michael McArthur and Professor Mervyn Bibb, is a spin-out company from the John Innes Centre, Norwich, a world renowned scientific centre of excellence in plant science and microbiology. The company was initially established through Plant Bioscience Ltd (PBL), the internationally regarded group specialising in early stage technology investment and IP management, on behalf of the JIC, the Sainsbury Laboratory and the Biotechnology and Biological Sciences Research Council. Procarta received seed funding in 2008 from the Rainbow and Iceni Seedcorn Funds and is currently headquartered on the Norwich Research Park.
TAXIS Pharmaceuticals is a privately held biopharmaceutical company dedicated to developing compounds to target the growing threat of antimicrobial resistance, including antibacterial and antiviral resistance. We are currently focused on antibiotic agents that employ novel mechanisms of action distinct from those currently in clinical use. Our team’s expertise in discovery chemistry, combined with our spirit of innovation, allows us to quickly pinpoint promising compounds that exhibit the key properties required for a clinical drug candidate.
Vaxxilon AG is focused on the discovery and development of innovative synthetic carbohydrate vaccines. Headquartered near Basel, Switzerland with research labs in Berlin, the Vaxxilon team is advancing several vaccine candidates for the prevention of major infectious diseases.
Integrated BioTherapeutics is a biotechnology company that focuses on discovering novel vaccines and therapeutics for emerging infectious diseases. Its antiviral pipeline includes unique pan-filovirus antibody candidates, vaccines, and a variety of other product candidates for emerging viruses.
Vaxcyte is a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide. The Company’s cell-free protein synthesis platform, comprising the XpressCFTM platform, exclusively licensed from Sutro Biopharma, Inc., together with Vaxcyte’s proprietary know-how, enables the design and production of protein carriers and antigens, the critical building blocks of vaccines, in ways that the Company believes conventional vaccine technologies currently cannot. In addition to its pneumococcal conjugate vaccines in development, VAX-24 and VAX-XP, Vaxcyte is leveraging its proprietary platform to advance other novel vaccines, including a prophylactic vaccine to prevent Group A Strep infections (VAX-A1) and a therapeutic vaccine to treat periodontal disease (VAX-PG).
Debiopharm Group is a biopharmaceutical development specialist that in-licenses promising biologics and small molecule drug candidates. They develop their products for global registration and maximum commercial potential for out-licensing to pharmaceutical partners for sales and marketing.
InhibOx is a pioneer in the development and application of new technologies to drive drug discovery. Their multidisciplinary research team has brought together breakthroughs in computational chemistry, cheminformatics, mathematics, cloud computing and software-as-a-service (SaaS) delivery methods to create DrugFinder: the next generation drug discovery platform.
ContraFect is a biotechnology company pioneering the use of monoclonal antibodies to treat life-threatening infectious diseases. It addresses multi-drug resistant infections using therapeutic products from its lysin and monoclonal antibody platforms to target the conserved regions of either bacteria or viruses. Its novel lysins are enzymes that are produced in the life cycle stage of bacteriophage, a virus that infects and kills bacteria. The company was founded in 2008 and is headquartered in Yonkers, New York.
Recida Therapeutics is a Biotechnology company.
Polyphor is a Swiss Pharma company focusing on the discovery and development of macrocycle drugs addressing high unmet medical needs. Polyphor was founded in 1996 and is a clinical stage, privately held Swiss specialty pharma company, based in Allschwil near Basel. It focuses on the development of macrocycle drugs that address antibiotic resistance and severe respiratory diseases.
ContraFect is a biotechnology company pioneering the use of monoclonal antibodies to treat life-threatening infectious diseases. It addresses multi-drug resistant infections using therapeutic products from its lysin and monoclonal antibody platforms to target the conserved regions of either bacteria or viruses. Its novel lysins are enzymes that are produced in the life cycle stage of bacteriophage, a virus that infects and kills bacteria. The company was founded in 2008 and is headquartered in Yonkers, New York.
Forge Therapeutics, Inc is a biotechnology company discovering and developing novel therapeutics using an innovative chemistry platform targeting metalloproteins. Forge uses a proprietary approach combining bioinorganic (study of metals in biology) and medicinal chemistry to generate selective inhibitors of this large class of targets.
SciBac is a developer of biotherapeutics intended to treat antibiotic diseases.The company's technology improves beneficial microorganisms using a patented MERGE platform that uses a type of directed evolution to increase therapeutic efficacy. Its first two therapeutics treat chronic infections in cystic fibrosis for Pseudomonas, Staph, Burkholderia, and NTM.
Summit Therapeutics is a clinical-stage drug discovery and development company. The company's new mechanism antibiotics are designed to become the new standards of care for the benefit of patients and create value for payors and healthcare providers.
BUGWORKS is a drug discovery company that aims to discover novel pharmaceutical assets for combating Antimicrobial Resistance (AMR). The company was founded in 2014 and is based in Bangalore, India.
Talis is dedicated to transforming diagnostic testing by developing and commercializing innovative products that are designed to enable accurate, low cost and rapid molecular testing for infectious diseases at the point-of-care. The company is developing the Talis One platform, a compact, sample-to-answer, cloud-enabled, molecular diagnostic platform.
Melinta Therapeutics is an antibiotics-focused company. The company’s mission is to discover, develop and commercialize urgently needed, groundbreaking antibiotics to overcome drug-resistant, life-threatening infections. The need for new therapies for drug-resistant infections is widely recognized as one of the most serious public health issues facing the world today. To meet this need, Melinta Therapeutics is rapidly progressing its late-stage investigational antibiotic, delafloxacin, which is currently in Phase 3 development for acute bacterial skin and skin structure infections (ABSSSI). In addition, Melinta is focused on its ongoing research program to develop a new class of antibiotics designed to overcome the resistant ESKAPE pathogens known to cause the majority of serious hospital infections and patient deaths. Melinta Therapeutics is privately held and backed by Vatera Healthcare Partners and Warburg Pincus.
Achaogen is a clinical stage biopharmaceutical company focused on the discovery and development of broad-spectrum antibiotics to treat multi-drug resistant bacterial infections. The company's most advanced drug candidate, ACHN-490, has demonstrated a positive safety and dosing profile in Phase 1 clinical testing and displayed broad spectrum efficacy in preclinical studies against systemic infections caused by multi-drug resistant (MDR) Gram-negative bacteria (e.g., E. coli, K. pneumoniae, and P. aeruginosa) and MRSA. In addition, the company is pursuing preclinical programs in several other areas of interest to combat the global emergence of bacterial resistance.
The purpose of Idorsia is to discover, develop and commercialize innovative medicines to help more patients. We have more ideas, we see more opportunities and we want to transform the horizon of therapeutic options. In order to achieve this, we will develop Idorsia into a leading biopharmaceutical company, with a strong scientific core. Headquartered in Switzerland – a biotech-hub of Europe – Idorsia is a high-potential biopharmaceutical company, specialized in the discovery, development and commercialization of innovative small molecules, with the aim of transforming the horizon of therapeutic options.
Shionogi provides pharmaceuticals, diagnostic reagents, and medical devices. They specialize in generic drug manufacturing. They engage in manufacturing, formulation, packaging, and analysis of commercialization research that spans late-stage drug discovery through commercial production.
HelixBind is a Massachusetts-based company that operates in the biotechnology sector. The company was founded in 2012 and is based in Worcester, Massachusetts.
T2 Biosystems is a private company developing a next-generation medical diagnostic platform that enables rapid and accurate diagnostic tests of all types on a single, easy-to-use instrument. The company's proprietary technology combines nanotechnology and miniaturized magnetic resonance (MR) technology and eliminates the need for costly and time-consuming sample preparation.
MicuRx discovers and develops novel antibiotics to combat drug resistant bacterial infections. Founded in 2007, MicuRx employs a hybrid U.S./China business model to capitalize on the global opportunities afforded by U.S. research and development coupled with the high-quality, cost-efficient scientific resources in China. Shanghai MicuRx was established and as of 2021 commercializes our agent, contezolid, in China. Global clinical studies are on-going.
Specific Diagnostics is a medical device company that provides a patented technology that leverages a low-cost small molecule sensor. Specific Diagnostics enables diagnostic products that simplify workflow and speed time-to-answer at a low cost.
Zikani Therapeutics are among the most widely used, most effective, and safest antibiotics to reach clinical practice; in fact, azithromycin has been among the world’s most widely used antibiotics for the past several years. But, while current macrolides are highly effective against some major bacteria, they are ineffective against others, especially gram-negative bacteria, the cause of most serious infections in the US. The first three generations of macrolides have very limited activity against gram-negative, and the sole drug in the current fourth-generation, solithromycin, has only slightly greater activity. Within other antibiotic classes, a limited number of compounds are in development to treat resistant gram-negative infections, and even fewer are available both intravenously and orally, as would be expected with macrolides. The company was founded in 2014 and is headquartered in Newton, Massachusetts.
Curza is a small-molecule therapeutics company that has developed several structurally distinct classes of proprietary drugs focused on infectious diseases and oncology. Curza’s lead program is a new class of broad spectrum antibiotics, focused on ESKAPE pathogens and drug-resistant Gram-negative bacteria. Inspired by a natural product, this class targets an unexploited binding site of the bacterial ribosome. With ever increasing reports of resistance to frontline therapies addressing Gram-negative bacteria, there is a critical need for new therapies and new therapies that work in new ways. However, very little can be found in the development pipeline. As a result, Curza’s compounds are addressing a major unmet medical need.
Inhibrx is a clinical-stage biotechnology company focused on developing a broad pipeline of novel biologic therapeutic candidates. Inhibrx utilizes diverse methods of protein engineering to address the specific requirements of complex target and disease biology, including its proprietary sdAb platform. The Inhibrx pipeline is focused on oncology, orphan diseases, and infectious diseases. Inhibrx has collaborations with Celgene and Bluebird Bio and has received awards from several granting agencies, including NIH, NIAID, and CARB-X.
Vedanta Biosciences is a developer of immunotherapies designed to treat immune-mediated and infectious diseases. It includes a suite of proprietary assays to select pharmacologically potent strains, vast proprietary datasets from human interventional studies, and facilities for cGMP-compliant manufacturing of rationally defined bacterial consortia in powder form to help physicians have access to live bacteria drugs to treat autoimmune and inflammatory diseases easily.
Integrated BioTherapeutics is a biotechnology company that focuses on discovering novel vaccines and therapeutics for emerging infectious diseases. Its antiviral pipeline includes unique pan-filovirus antibody candidates, vaccines, and a variety of other product candidates for emerging viruses.
Amicrobe, Inc. is an advanced biomaterials company with innovative product candidates designed to prevent and treat infections. The Company’s new, synthetic block copolypeptides (A-Blocks) are engineered to provide broad antimicrobial activity and superior tissue coverage when our natural barriers of defense are broken in surgery, trauma / burns, and diabetic foot ulcers.
Entasis Therapeutics is developing a portfolio of innovative cures for serious drug-resistant bacterial infections, a global health crisis affecting the lives of millions of patients. Entasis’ anti-infective discovery platform has produced a pipeline of meaningfully differentiated programs which target serious bacterial infections, including ETX2514SUL (targeting Acinetobacter baumannii infections), ETX0282CPDP (targeting Enterobacteriaceae infections), and zoliflodacin (targeting Neisseria gonorrhoeae).
Seres Therapeutics is a clinical-stage biotherapeutic company that develops ecobiotic therapeutic products. They engaged in developing biological drugs which are referred to as ecobiotic microbiome therapeutics. The company is a group of experts in microbiome research and drug development. Its executive team, board of directors, and scientific advisory board have a wealth of experience in the development, regulatory approval, and profitable commercialization of a wide range of therapeutic products.
EligoChem has developed a proprietary and patentable technology that facilitates the design of highly water-soluble drugs that are absorbed well by the human body. One in fifteen known drug compounds have this combination of properties, but they are present in only one in ten thousand compounds in current pharma screening collections. This technology is particularly suited to antibiotic drug discovery.
Venatorx Pharmaceuticals is a private company that focuses on the discovery and development of novel anti-infectives to treat multi-drug-resistant (MDR) bacterial infections and hard-to-treat viral infections. The company was founded in 2010 and is headquartered in Malvern, Pennsylvania.
Antabio is a private biopharmaceutical company developing novel antibacterial resistance-breakers to treat drug-resistant infections in areas of highest unmet medical need. It develops stand-alone inhibitors of bacterial metalloenzymes that can be combined with various antibiotics to restore their activity against the most critical pathogens. The company's novel inhibitor of bacterial Metallo ß-lactamases (“MBLs”) which will be combined with a carbapenem to fill an important gap in the treatment of drug-resistant infections. They develop a novel, safe and efficacious inhibitor of bacterial Metallo ß-lactamases to be combined with a carbapenem for the treatment of drug-resistant nosocomial infections. Antabio received a Wellcome Trust Seeding Drug Discovery Award. The company was founded in 2009 and is headquartered in Labege, France.
Debiopharm Group is a biopharmaceutical development specialist that in-licenses promising biologics and small molecule drug candidates. They develop their products for global registration and maximum commercial potential for out-licensing to pharmaceutical partners for sales and marketing.
Achaogen is a clinical stage biopharmaceutical company focused on the discovery and development of broad-spectrum antibiotics to treat multi-drug resistant bacterial infections. The company's most advanced drug candidate, ACHN-490, has demonstrated a positive safety and dosing profile in Phase 1 clinical testing and displayed broad spectrum efficacy in preclinical studies against systemic infections caused by multi-drug resistant (MDR) Gram-negative bacteria (e.g., E. coli, K. pneumoniae, and P. aeruginosa) and MRSA. In addition, the company is pursuing preclinical programs in several other areas of interest to combat the global emergence of bacterial resistance.
Iterum Therapeutics is a clinical-stage pharmaceutical company that develops significantly differentiated anti-infectives. It aimed at combatting the global crisis of multi-drug resistant (MDR) pathogens to significantly improve the lives of people affected by serious and life-threatening diseases around the world. Iterum’s first product is a novel anti-infective compound that has demonstrated potent in-vitro activity vs. a wide variety of gram-negative, gram-positive, and anaerobic bacteria resistant to other antibiotics.
Capitalizing on breakthrough synthetic chemistry, Tetraphase Pharmaceuticals is leveraging a dynamic drug engine targeted at several significant disease categories.
Microbiotix, Inc. is a clinical stage biopharmaceutical company focused on the discovery and development of proprietary small molecule drugs that target serious infectious diseases, including multi-drug resistant pathogens.
Entasis Therapeutics is developing a portfolio of innovative cures for serious drug-resistant bacterial infections, a global health crisis affecting the lives of millions of patients. Entasis’ anti-infective discovery platform has produced a pipeline of meaningfully differentiated programs which target serious bacterial infections, including ETX2514SUL (targeting Acinetobacter baumannii infections), ETX0282CPDP (targeting Enterobacteriaceae infections), and zoliflodacin (targeting Neisseria gonorrhoeae).
Redx Pharma is a drug discovery and development company formed in 2010. It is focused on improving the characteristics of existing drug classes to create best-in-class new drugs in the areas of cancer, infection and autoimmune disease. The company's work has been endorsed by partnerships with global pharmaceutical companies and the NHS. Redx Pharma has three subsidiaries: Redx Oncology Ltd launched in April 2012, Redx Anti-Infectives Ltd launched in April 2013 and Redx Immunology Ltd launched in May 2015.
Spero Therapeutics, a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializes in developing novel therapies for multi-drug resistant (MDR) bacterial infections and rare diseases. Its key product candidates include tebipenem pivoxil hydrobromide, an oral carbapenem-class antibiotic intended for adults with MDR Gram-negative infections, and SPR206, an intravenous agent targeting MDR Gram-negative infections in hospital settings. Additionally, the company is advancing SPR720, an oral antibiotic designed for treating pulmonary non-tuberculous mycobacterial disease. Spero Therapeutics has established various collaborations and license agreements to support the development and commercialization of its products, including partnerships with Meiji Seika Pharma, Everest Medicines, and the Bill & Melinda Gates Medical Research Institute. Founded in 2013, Spero aims to address the critical need for effective treatments against serious bacterial infections using innovative approaches and mechanisms.
Forge Therapeutics, Inc is a biotechnology company discovering and developing novel therapeutics using an innovative chemistry platform targeting metalloproteins. Forge uses a proprietary approach combining bioinorganic (study of metals in biology) and medicinal chemistry to generate selective inhibitors of this large class of targets.
ContraFect is a biotechnology company pioneering the use of monoclonal antibodies to treat life-threatening infectious diseases. It addresses multi-drug resistant infections using therapeutic products from its lysin and monoclonal antibody platforms to target the conserved regions of either bacteria or viruses. Its novel lysins are enzymes that are produced in the life cycle stage of bacteriophage, a virus that infects and kills bacteria. The company was founded in 2008 and is headquartered in Yonkers, New York.
Cidara Therapeutics is a biotechnology company that specializes in the fields of healthcare and therapeutics. The company focuses on developing innovative therapies to treat life-threatening illnesses exacerbated by deficiencies of the human immune system. Cidara Therapeutics was founded in 2012 and headquartered in San Diego, California.
The University of Edinburgh, founded in 1583, is a prestigious non-profit educational institution located in Edinburgh, Scotland. It is the sixth-oldest university in the English-speaking world and one of Scotland's ancient universities. The university offers a wide range of graduate and postgraduate courses across various fields, including science, engineering, arts, and humanities. Its Medical School is particularly renowned, contributing to advancements in medical education and research. The university is committed to academic excellence and plays a vital role in the educational landscape of the United Kingdom and beyond.
Developing the next generation of antibiotics with novel mechanisms of action.